← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
Closed-loop transcranial focused ultrasound to restore hippo (SST) — 0.00 eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote (EIF2S1,eIF2α,PERK,GCN2,ATF4,TOMM20,TIMM23,NDUFS1,NDUFS3,COX4I1,COX5A,mitochondrial protein import) — 0.00 TBK1 Loss Triggers eIF2α-Mediated Translational Repression T (TBK1, EIF2S1) — 0.00 LAMP1 Overexpression to Enhance Lysosomal Capacity Independe (LAMP1) — 0.00 LAMP2A Upregulation to Enhance Chaperone-Mediated Autophagy (LAMP2A) — 0.00 Alpha-theta entrainment therapy to enhance default mode netw (SST) — 0.00 Cell-Type-Specific TFEB Modulation Combined with Trehalose f (TFEB) — 0.00 LDLR-Primed LRP1 Transcytosis with pH-Responsive Escape Stra (LDLR) — 0.00 TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio (TBK1 → NF-κB / IRF3 / p62-autophagy / SASP effectors) — 0.00 Closed-loop transcranial focused ultrasound with gamma entra (PVALB) — 0.00 LDLR-Mediated Neurosteroid Precursor Delivery Strategy (LDLR) — 0.00 GLUT1-Mediated Carrier-Conjugate Delivery Strategy (LDLR) — 0.00 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.97 GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl (GRIN2B) — 0.96 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.96 Cortico-Striatal Synchrony Restoration via NMDA Modulation (GRIN2B) — 0.95 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.95 Plasma NfL Elevation Secondary to BBB-Associated Transport D (NEFL) — 0.94 Microglial-Mediated Tau Clearance Dysfunction via TREM2 Rece (MAPT) — 0.94 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.92 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 eIF2α Phosphorylation Imbalance Creates Integrated Stress Re (EIF2S1,eIF2α,PERK,GCN2,ATF4,ATF5,CHOP,DDIT3,integrated stress response,protein synthesis) — 0.90 APOE-Dependent Autophagy Restoration (MTOR) — 0.89 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 p38α Inhibitor and PRMT1 Activator Combination to Restore Ph (MAPK14/PRMT1) — 0.89 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.89 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.89 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.89
Add
|
× Caloric Restriction Mimet
AMPK,PRKAA1,PRKAA2,SIRT1,MTOR,RPTOR,PPARGC1A,FOXO3,FOLH1 · neurodegeneration · -
Composite 0.640
Price $0.54
Evidence For 0
Evidence Against 0
Caloric restriction (CR) extends lifespan and improves neuronal function across species through a network of interconnected metabolic sensors: AMPK (activated by increased AMP/ATP ratio), SIRT1 (activated by increased NAD+/NADH ratio), and mTORC1 (inhibited by reduced amino acid signaling and increased AMPK activity). This hypothesis proposes that a rationally designed combination of FDA-approved caloric restriction mimetics—metformin (AMPK activator, via mitochondrial complex I inhibition), res
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Caloric Restriction Mimetic Co Mechanistic 0.650 Evidence 0.750 Novelty 0.450 Feasibility 0.700 Impact 0.850 Druggability 0.000 Safety 0.000 Competition 0.000 Data 0.000 Reproducible 0.400 KG Connect 0.500
Evidence Caloric Restriction Mimetic Combination Therapy (Metformin + No evidence citations yet
Price History Overlay